BioSpace News Archive

Nabriva Therapeutics plc today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright Global Investment Conference.

Aileron Therapeutics today announced that it will host a virtual KOL investor event on Thursday, May 19, 2022, at 4:00 pm ET/ 1:00 pm PT.

ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Corporation”) , is pleased to announce the Annual and Special Meeting of Shareholders (the “Meeting”) of ProMIS was held online by virtual web-cast meeting, on Thursday, May 12, 2022 at 9:00 a.m. (Pacific time).

Biofrontera Inc. (Nasdaq: BFRI) (the “Company”) , a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial results for the three months ended March 31, 2022, and provided a business update.

Nanoscope Therapeutics Inc ., a clinical-stage biotechnology company developing optogenetic therapies for treatment of retinal degenerative diseases, today announced four presentations on the Company’s clinical development and research programs at the 25 th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), May 16-19, 2022.

Bristol Myers Squibb and LOTTE Corporation announced that LOTTE has agreed to purchase Bristol Myers Squibb’s manufacturing facility in East Syracuse, New York.

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced its financial and operational results and provided an update for the first quarter ended March 31, 2022.

VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) today announces that will be presenting at the Roth Canada Showcase Day, which will be held in-person at 1 Hotel Central Park, 1414 Avenue of the Americas (58th Street), New York, NY 10019.

Recordati Rare Diseases Inc. announced today that the Phase III LINC 3 study demonstrates ISTURISA® (osilodrostat) improves physical features associated with hypercortisolism in patients with Cushing’s disease.

Spectral Medical Inc. announced that Chris Seto, CEO and Dr. Jon Kellum, CMO of Spectral Medical, have been invited to present at the Spring Into Action - Best Ideas Investor Conference, which is being held virtually May 16th-20th, 2022.